FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2410-2411 December 6, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: In their review of anabolic therapies for osteoporosis, Canalis et al. (Aug. 30 issue)¹ mention contraindications to teriparatide use, including skeletal malignant conditions. We wish to add an additional caution concerning the use of this drug in patients with a history of cancer. Patients with non–small-cell lung cancer, breast cancer, and other cancers have been shown to have micrometastatic tumor cells in the bone marrow that are associated with poor outcomes.^2,3 It is not known whether patients without evidence of disease for many years have "micrometastases" in the bone marrow as well. The high-bone-turnover state (sequential osteoblastic . . . [Full Text of this Article]

This article has been cited by other articles:

• Puig-Domingo, M., Diaz, G., Nicolau, J., Fernandez, C., Rueda, S., Halperin, I. (2008). Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur J Endocrinol 159: 653-657 [Abstract] [Full Text]